Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.91 |
| ▸ | AKT2 | P31751 | 15/20 | 0.91 |
| ▸ | AKT3 | Q9Y243 | 12/20 | 0.91 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2191503 | 0.95 | AKT1 (1.00) | AKT1AKT2AKT3CYP2C8CYP2C9 | |
| SCHEMBL31455748 | 0.94 | AKT1 (0.92) | AKT1AKT2AKT3CYP2C8CYP2C9 | |
| SCHEMBL31455728 | 0.94 | AKT1 (0.92) | AKT1AKT2AKT3CYP2C8CYP2C9 | |
| SCHEMBL31455890 | 0.93 | AKT1 (0.89) | AKT1AKT2AKT3CYP2C8CYP2C9 | |
| SCHEMBL31455619 | 0.91 | AKT1 (0.86) | AKT1AKT2AKT3CYP2C8CYP2C9 | |
| SCHEMBL31455677 | 0.91 | AKT1 (0.84) | AKT1AKT2AKT3CYP2C8CYP2C9 | |
| SCHEMBL31455807 | 0.91 | AKT1 (0.86) | AKT1AKT2AKT3CYP2C8CYP2C9 | |
| SCHEMBL2188306 | 0.91 | AKT1 (0.92) | AKT1AKT2AKT3CYP2C8CYP2C9 | |
| SCHEMBL2193611 | 0.91 | AKT1 (0.92) | AKT1AKT2AKT3CYP2C8CYP2C9 | |
| SCHEMBL31420341 | 0.91 | AKT1 (0.83) | AKT1AKT2AKT3CYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025059562-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AND METHODS OF TREATING DISEASE USING SAME | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |